The Filing Desk

DBV Technologies vs X4 Pharmaceuticals

DBV Technologies DBVT · X4 Pharmaceuticals XFOR · Biotechnology

X4 Pharmaceuticals reported revenue of $6 million in fiscal 2025, 1.2 times DBV Technologies' $6 million in fiscal 2025. DBV Technologies' revenue grew 35.8% in its latest year, and X4 Pharmaceuticals' grew 150.0%. DBV Technologies had an operating margin of -2609.2%, against -1336.7% at X4 Pharmaceuticals. Free cash flow was −$122 million at DBV Technologies and −$86 million at X4 Pharmaceuticals.

Side by side

DBV TechnologiesX4 Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$6M$6M
Revenue growth35.8%150.0%
Revenue growth a year, last 5 years−13.1%16.7%
Gross margin—11.4%
Operating margin−2,609.2%−1,336.7%
Net margin−2,607.3%−1,218.5%
Free cash flow−$122M−$86M
Free cash flow margin−2,159.6%−1,317.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count43.9%531.0%
Last close$9.42$2.96
P/E at the last close——
Insider trades, last 12 monthssold $15.5 millionsold $428,889
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
DBV TechnologiesX4 Pharmaceuticals
Operating margin
Percent of revenue
DBV TechnologiesX4 Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
DBV TechnologiesX4 Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the DBV Technologies and X4 Pharmaceuticals pages.